Incyte (INCY) is down about 3.75% today, extending a post-earnings slide after the company’s first-quarter 2026 report. The catalyst is guidance: Incyte’s full-year 2026 revenue outlook of $4.77 billion to $4.94 billion landed well below a roughly $5.57 billion Street consensus, outweighing the quarterly beat and pushing shares lower as investors reset expectations for the year. (investing.com)

In Q1 2026, Incyte reported adjusted EPS of $1.81 on total revenue of $1.27 billion, both ahead of estimates cited by market reports. However, the guidance gap is large enough to drive sentiment: the midpoint of management’s revenue range implies a meaningful shortfall versus consensus, raising concerns about the pace of growth for the remainder of 2026 and the durability of the company’s current earnings power. (investing.com)

Management pointed to solid commercial execution, with Q1 net sales up year over year and product-level strength including Jakafi and Opzelura. The market’s focus, though, remains on what the guidance implies about the next few quarters—particularly whether competitive dynamics, mix, or cadence of product demand will keep full-year revenue below prior expectations even after a strong start to the year. (investing.com)

Near-term trading in INCY is likely to track estimate revisions and follow-on analyst commentary after the Q1 print. Investors will be watching whether consensus revenue and earnings forecasts move down toward management’s range, and whether upcoming regulatory and pipeline milestones can shift the narrative back toward growth acceleration later in 2026. (investing.com)